KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Equivalents (2016 - 2025)

Gsk (GSK) has 7 years of Cash & Equivalents data on record, last reported at $3.6 billion in Q4 2023.

  • For Q4 2023, Cash & Equivalents fell 16.55% year-over-year to $3.6 billion; the TTM value through Dec 2023 reached $3.6 billion, down 16.55%, while the annual FY2023 figure was $3.7 billion, 20.74% down from the prior year.
  • Cash & Equivalents reached $3.6 billion in Q4 2023 per GSK's latest filing, down from $4.4 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $8.3 billion in Q4 2020 and bottomed at $3.6 billion in Q4 2023.
  • Average Cash & Equivalents over 4 years is $5.6 billion, with a median of $5.2 billion recorded in 2019.
  • Peak YoY movement for Cash & Equivalents: soared 37.28% in 2020, then dropped 16.55% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $6.1 billion in 2019, then surged by 37.28% to $8.3 billion in 2020, then tumbled by 47.44% to $4.4 billion in 2022, then decreased by 16.55% to $3.6 billion in 2023.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $3.6 billion in Q4 2023, $4.4 billion in Q4 2022, and $8.3 billion in Q4 2020.